Lantheus Holdings saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 92 to 96.
The new score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. Winning stocks often have a 95 or higher score in the early stages of a new price run, so that's a good item to have on your checklist when looking for the best stocks to buy and watch.
Lantheus Holdings is not currently near a proper buy zone. See if the stock goes on to form a new chart pattern and offer a new buying opportunity.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock earns an 84 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 84% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company posted -9% EPS growth. Top line growth came in at 10%, down from 18% in the previous quarter.
Lantheus Holdings holds the No. 6 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
